This study is for patients that have been diagnosed with metastatic castration-resistant prostate cancer. The study is testing an investigational drug called JANX007. Investigational means it has not been approved by the United States Food and Drug Administration (FDA). The primary purpose of the study is to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of JANX007 when administered as a single agent. The drug is given to participants by IV infusion. Participants in this study can expect to be in this study until disease progression or unacceptable toxicity.

The study is designed for patients with Estrogen Receptor (ER) positive, HER2-negative advanced breast cancer resistance to prior adjuvant endocrine treatment. The purpose of the study is to determine the effectiveness of Giredestrant compared with Fulvestrant in combinationof CDK4/6i (Palbociclib, Ribociclib and Abemaciclib). The study drug being utilized is giredestrant. The FDA approved drugs will also be utilized: Zoladex and Lupron (LHRH - Luteinizing hormone-releasing hormone agonists) drugs; as well as, Palbociclib, Ribociclib , Fulvestrant, and Abemaciclib.

The study is for patient that are receiving camizestrant as a treatment. The main purpose of study is to change the dosage of camizestrant from 150mg to 75mg. This change was prompted by updated, emerging data from ongoing studies showing
no difference in efficacy between the 75 mg and 150 mg doses. Subject can expect to be in this study for up to 24 months.

The main purpose of this study is to measure overall survival (OS) and safety of ivonescimab (study drug) when combined with chemotherapy drugs carboplatin, paclitaxel or nab-paclitaxel compared to pembrolizumab combined with chemotherapy drugs carboplatin, paclitaxel or nab-paclitaxel. Participants will undergo screening procedures done to determine if they meet the requirements to be in this study. Screening will be completed within 28 days before receiving the study drug. Many of these screening measures are likely part of regular cancer care and may be done even if it turns out that you do not participate in the research study.

Once enrolled in the study, participants will visit the clinic every three weeks for 4 cycles of ivonescimab plus chemotherapy or pembrolizumab and chemotherapy for up to four infusions, followed by ivonescimab or pembrolizumab every three weeks for up to 24 months. If a participant's physician decides to use nab-paclitaxel chemotherapy for the first 4 cycles of treatment, the schedule of treatment is different and will require that the participant comes to the clinic for this infusion on days 1, 8, and 15 of each cycle. There will be follow-up check-up visits with the study team approximately 7 days, 30 days and 90 days after the last treatment or before the participant starts a new treatment for the cancer. Ninety (90) days after the participant stops taking the study drug, there will be a call or a visit scheduled to review how the they are feeling. This is a survival call/visit and will happen every 90 days until the end of the study. Participation in this study will last about 4 years, 2 years in active treatment and 2 years in follow up.

Depression is common among cancer survivors but current screening approaches are not adequate. To help develop better strategies to screen for depression among cancer survivors, we will conduct a pilot randomized controlled trial with cancer survivors to evaluate whether a text message based approach to depression screening is feasible, acceptable, and potentially more effective than existing standard of care approaches to depression screening among cancer survivors.

Depression is common among cancer survivors but current screening approaches are not adequate. To help develop better strategies to screen for depression among cancer survivors, we will conduct a pilot randomized controlled trial with cancer survivors to evaluate whether a text message based approach to depression screening is feasible, acceptable, and potentially more effective than existing standard of care approaches to depression screening among cancer survivors.

Depression is common among cancer survivors but current screening approaches are not adequate. To help develop better strategies to screen for depression among cancer survivors, we will conduct a pilot randomized controlled trial with cancer survivors to evaluate whether a text message based approach to depression screening is feasible, acceptable, and potentially more effective than existing standard of care approaches to depression screening among cancer survivors.

Depression is common among cancer survivors but current screening approaches are not adequate. To help develop better strategies to screen for depression among cancer survivors, we will conduct a pilot randomized controlled trial with cancer survivors to evaluate whether a text message based approach to depression screening is feasible, acceptable, and potentially more effective than existing standard of care approaches to depression screening among cancer survivors.

Depression is common among cancer survivors but current screening approaches are not adequate. To help develop better strategies to screen for depression among cancer survivors, we will conduct a pilot randomized controlled trial with cancer survivors to evaluate whether a text message based approach to depression screening is feasible, acceptable, and potentially more effective than existing standard of care approaches to depression screening among cancer survivors.

Depression is common among cancer survivors but current screening approaches are not adequate. To help develop better strategies to screen for depression among cancer survivors, we will conduct a pilot randomized controlled trial with cancer survivors to evaluate whether a text message based approach to depression screening is feasible, acceptable, and potentially more effective than existing standard of care approaches to depression screening among cancer survivors.